CONCLUSIONS:
Combined weekly cDC (concurrent docetaxel and carboplatin) appeared to
be cost-effective compared with sDC (sequential docetaxel and carboplatin ) as treatment strategy for patients
with platinum-sensitive ovarian cancer, even when accounting for
slightly lower QoL during treatment.